Kovacs work focuses on enhancing cognitive functions and brain health through innovative, efficient neuroactive compounds that overcome traditional pharmacokinetic challenges
Higher doses (4.5 mg) were evaluated but discontinued due to excessive gastrointestinal side effects without proportional benefits[7]
Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
demonstrated that anti-depressive effects of fluoxetine or imipramine were lost following x-ray ablation of cell proliferation in the SGZ indicating an important contribution of adult neurogenesis in the mood-modulating effects of 5-HT [132]
For complete coverage of GHK-Cu's research history, see GHK-Cu: The Anti-Aging Copper Peptide with Over 100 Published Studies
John Bacha, specializing in bariatric surgery, offers expert guidance and personal insights to help patients achieve their weight loss goals
